Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Cangene Corporation
ClinicalTrials.gov Identifier:
NCT00768287
First received: October 7, 2008
Last updated: January 29, 2014
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2014
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
No publications provided by Cangene Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):